2021: The Year of Advances in Unresectable HCC?

EP. 11: KEYNOTE-240 and HIMALAYA Trials in Advanced HCC

March 31st 2021

A review of currently available ongoing data for unresectable HCC (hepatocellular carcinoma), including data from the HIMALAYA trial.

EP. 12: Approaching Second-Line Therapy in HCC

March 31st 2021

Amit Singal, MD, shares his thoughts on approaching second-line therapy for HCC (hepatocellular carcinoma) after first-line atezolizumab-bevacizumab as well as options for patients with Child-Pugh B disease who are ineligible for frontline atezolizumab-bevacizumab.

EP. 13: Role of VEGF TKIs for Second-Line Therapy in HCC

April 7th 2021

Considerations for selecting a VEGF TKI (tyrosine kinase inhibitor) in the second-line setting for the management of HCC (hepatocellular carcinoma).

EP. 14: CELESTIAL and RESORCE Trials in HCC

April 7th 2021

Amit Singal, MD, comments on the use of cabozantinib in patients with Child-Pugh A and Child-Pugh B disease as well as regorafenib in advanced stage HCC (hepatocellular carcinoma).

EP. 15: Sequencing With Anti-PD-1 Antibodies in HCC

April 14th 2021

Amit Singal, MD; Masatoshi Kudo, MD, PhD; and Stephen L. Chan, MD, share their personal approaches to sequencing with an anti-PD-1 antibody after first-line atezolizumab-bevacizumab in HCC (hepatocellular carcinoma).

EP. 16: Using AFP as a Biomarker in HCC

April 14th 2021

Stephen L. Chan, MD, comments on the use of AFP as a predictive biomarker in HCC (hepatocellular carcinoma) and the current use of ramucirumab.

EP. 17: Future Directions of HCC

April 14th 2021

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).